MedPath

Diphenhydramine

Generic Name
Diphenhydramine
Brand Names
Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil
Drug Type
Small Molecule
Chemical Formula
C17H21NO
CAS Number
58-73-1
Unique Ingredient Identifier
8GTS82S83M
Background

Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system . While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use .

Diphenhydramine is also used in combination with 8-chlorotheophylline as the anti-nausea drug Dimenhydrinate where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system .

Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.

Indication

Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea .

Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:

i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated ;

ii) the active treatment of motion sickness ; and

iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents .

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes
Associated Therapies
Airway secretion clearance therapy, Expectorant

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Phase 1
Active, not recruiting
Conditions
Recurrent Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Hairy Cell Leukemia
Refractory Hematologic Malignancy
Refractory Hodgkin Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Systemic Mastocytosis
Interventions
First Posted Date
2020-12-23
Last Posted Date
2024-12-31
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
13
Registration Number
NCT04681105
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2020-12-09
Last Posted Date
2023-10-12
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
50
Registration Number
NCT04660799
Locations
🇨🇳

The First Hospital of Jilin University, Changchun City, China

🇨🇳

Peking University Third Hospital, Beijing, China

🇨🇳

Fujian Provincial Cancer Hospital, Fuzhou City, China

and more 5 locations

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Phase 3
Active, not recruiting
Conditions
Primary Membranous Nephropathy
Interventions
First Posted Date
2020-11-16
Last Posted Date
2025-03-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
142
Registration Number
NCT04629248
Locations
🇮🇹

A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia, Italy

🇦🇷

Hospital Britanico Buenos Aires, Buenos Aires, Argentina

🇫🇷

Hopital Henri Mondor, Creteil, France

and more 47 locations

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase 1
Completed
Conditions
Mantle Cell Lymphoma
B-Cell Lymphoma
Marginal Zone Lymphoma
Chronic Lymphocytic Lymphoma
Follicular Lymphoma
Interventions
Drug: Prednisone/prednisolone
Diagnostic Test: CT Scan chest/abdomen/pelvis
Diagnostic Test: MRI
Diagnostic Test: 18-FDG-PET
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
First Posted Date
2020-10-23
Last Posted Date
2025-02-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
11
Registration Number
NCT04599634
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2020-10-08
Last Posted Date
2024-06-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
59
Registration Number
NCT04580121
Locations
🇮🇹

Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy

🇺🇸

UC Davis Comprehensive Cancer Center, Sacramento, California, United States

🇩🇰

Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark

and more 20 locations

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Conditions
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
First Posted Date
2020-07-02
Last Posted Date
2023-05-06
Lead Sponsor
Mesoblast International Sàrl
Registration Number
NCT04456439

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Phase 2
Recruiting
Conditions
Gastric Cancer
Stomach Cancer
Interventions
Radiation: 3D conformal or intensity modulated radiotherapy
Procedure: Surgical resection
Radiation: Adjuvant Chemotherapy
First Posted Date
2020-03-16
Last Posted Date
2023-11-14
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
29
Registration Number
NCT04308837
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

Mount Sinai St. Luke's, New York, New York, United States

🇺🇸

Mount Sinai West, New York, New York, United States

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

First Posted Date
2020-03-04
Last Posted Date
2023-06-27
Lead Sponsor
Sanofi
Target Recruit Count
23
Registration Number
NCT04294459
Locations
🇺🇸

Investigational Site Number :8400004, Houston, Texas, United States

🇺🇸

Investigational Site Number :8400002, New York, New York, United States

🇺🇸

Investigational Site Number :8400001, Rochester, Minnesota, United States

and more 3 locations

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

First Posted Date
2020-02-17
Last Posted Date
2024-10-31
Lead Sponsor
Sanofi
Target Recruit Count
337
Registration Number
NCT04270409
Locations
🇦🇺

Investigational Site Number :0360008, Liverpool, New South Wales, Australia

🇯🇵

Investigational Site Number :3920001, Shibuya-ku, Tokyo, Japan

🇱🇹

Investigational Site Number :4400001, Vilnius, Lithuania

and more 102 locations

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Phase 2
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2020-02-13
Last Posted Date
2025-05-06
Lead Sponsor
University of Miami
Target Recruit Count
310
Registration Number
NCT04268498
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath